Owens & Minor (NYSE:OMI) Updates Q4 2024 Earnings Guidance

Owens & Minor (NYSE:OMI) issued an update on its fourth quarter 2024 earnings guidance on Monday morning. The company provided earnings per share (EPS) guidance of 0.520-0.550 for the period, compared to the consensus estimate of 0.530. The company issued revenue guidance of $2.7 billion-$2.7 billion, compared to the consensus revenue estimate of $2.7 billion. Owens & Minor also updated its FY 2024 guidance to 1.500-1.530 EPS.

Owens & Minor Stock Performance

Shares of Owens & Minor stock traded down $3.69 during trading hours on Monday, hitting $10.56. 1,369,382 shares of the company’s stock traded hands, compared to its average volume of 535,474. The stock has a market capitalization of $813.90 million, a price-to-earnings ratio of -16.24, a PEG ratio of 0.40 and a beta of 0.48. Owens & Minor has a 12-month low of $10.58 and a 12-month high of $28.35. The company has a debt-to-equity ratio of 2.11, a current ratio of 1.09 and a quick ratio of 0.45. The company has a fifty day simple moving average of $13.86 and a 200-day simple moving average of $14.32.

Owens & Minor (NYSE:OMI) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.41 by $0.01. The business had revenue of $2.72 billion during the quarter, compared to the consensus estimate of $2.68 billion. Owens & Minor had a negative net margin of 0.46% and a positive return on equity of 14.60%. The firm’s quarterly revenue was up 5.0% compared to the same quarter last year. During the same quarter last year, the company posted $0.44 earnings per share. Equities research analysts anticipate that Owens & Minor will post 1.49 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on OMI shares. UBS Group lowered their price target on shares of Owens & Minor from $28.00 to $25.00 and set a “buy” rating on the stock in a report on Tuesday, November 5th. Citigroup lowered their target price on Owens & Minor from $21.00 to $18.50 and set a “buy” rating on the stock in a research note on Tuesday, November 5th. Barclays cut their price target on Owens & Minor from $18.00 to $14.00 and set an “equal weight” rating for the company in a research note on Tuesday, November 5th. Finally, Robert W. Baird decreased their price objective on Owens & Minor from $19.00 to $14.00 and set a “neutral” rating for the company in a report on Tuesday, November 5th. Two analysts have rated the stock with a sell rating, five have given a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, Owens & Minor currently has an average rating of “Hold” and a consensus target price of $18.50.

Insider Activity at Owens & Minor

In other Owens & Minor news, CFO Jonathan A. Leon sold 5,282 shares of the stock in a transaction that occurred on Thursday, November 21st. The shares were sold at an average price of $11.82, for a total value of $62,433.24. Following the sale, the chief financial officer now directly owns 130,822 shares in the company, valued at $1,546,316.04. This represents a 3.88 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 2.62% of the stock is currently owned by corporate insiders.

Owens & Minor Company Profile

Owens & Minor, Inc, together with its subsidiaries, operates as a healthcare solutions company worldwide. It operates through Products & Healthcare Services and Patient Direct segments. The Products & Healthcare Services segment offers a portfolio of products and services to healthcare providers and manufacturers.